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The transcription of mitochondrial DNA has been studied for 30 years. However, many of the earlier observations are still unsolved. In this
review we will recall the basis of mitochondrial DNA transcription, established more than twenty years ago, will include some of the recent
progress in the understanding of this process and will suggest hypotheses for some of the unexplained topics. Moreover, we will show some
examples of mitochondrial pathology due to altered transcription and RNA metabolism.
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HumanmitochondrialDNA (mtDNA) is a super-coiled double-
stranded closed circular molecule of approximately 16.5 kilobases
(kb) [1,2]. There are several copies per mitochondrion and many
hundred mitochondria per cell.
This molecule encodes 37 genes, 2 ribosomal RNAs (12 S and
16 S rRNAs), 22 transfer RNAs (tRNAs) and 13 polypeptides, all
of them components of the oxidative phosphorylation (OXPHOS)
system: seven (ND1–ND6 and ND4L) of the 46 complex I
(NADH:ubiquinone oxidoreductase) polypeptides; one (apocy-
tochrome b) of the 11 complex III (ubiquinol:cytochrome c
oxidoreductase) subunits; three (COI–COIII) of the 13 complex
IV (cytochrome c oxidase) polypeptides and two (ATP6 and
ATP8) of the 16 complex V (ATP synthase) subunits.
According to their G+T bases composition, which confers to
them a different density, the strands were denominated heavy (H)
and light (L). One polypeptide (ND6) and eight tRNA genes are
encoded in the L-strandwhile the rest are encoded in theH-strand.
The genetic organization of the mtDNA is extremely compact:
polypeptide, tRNAand rRNAgenes are smaller than the cytosolic
and prokaryotic counterparts [3], there are overlapping genes, the
3′-end CCA of the tRNAs and even some termination codons are⁎ Corresponding author. Tel.: +34 976761640; fax: +34 976761612.
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doi:10.1016/j.bbabio.2006.03.023not mitochondrial encoded; the smaller size of the rRNAs has
required the recruitment of new ribosomal proteins to substitute
the lost functions of the removed rRNA segments [4], there are no
intronic sequences and almost no non-coding nucleotides bet-
ween genes.
A non-coding region (control region) of approximately 1.1 kb,
located between the tRNAPhe and tRNAPro, contains the origin of
replication for the heavy strand (OH), the transcription promoters
(LSP and HSP, light and heavy strand promoters, respectively)
and the regulatory elements for the mtDNA expression [multiple
TFAM binding sites, 3 conserved sequence blocks (CSB) and a
termination associated sequence (TAS)]. However, the function
for most of the control region is unknown and it is unexpected that
in such an otherwise compact genome there are regions without
any apparent function. In fact, the central domain of the control
region, with as yet unknown role, is more evolutionary conserved
than the known regulatory elements [5,6] and it might be involved
in the replication or expression of the mitochondrial genetic
information.
2. Mitochondrial RNA synthesis and processing
RNA is synthesized in human mitochondria by means of
three transcription units that start at three different initiation
points, one for the L-strand (L) and two for the H-strand (H1 and
H2), that transcribe three polycistronic molecules [7–10] (Fig.
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One of them, more frequently used, starts at the initiation site H1,
located 16 nt upstream of the tRNAPhe gene (position 561) and
ends at the 3′-end of the 16S rRNA. This transcription unit is
responsible for the synthesis of the two rRNAs, tRNAPhe and
tRNAVal. The transcriptional activity of this unit is linked to a
termination event that take place immediately downstream from
16 S rRNA, inside the gene for tRNALeu [8,11]. The second
transcription unit, less frequently used than the previous one,
starts at the initiation site H2, 2 nt upstream of the 5′-end of the
12 S rRNA gene (position 646) [8,10] and produces a
polycistronic molecule covering almost the whole H-strand.
The mRNAs for 12 polypeptides and 14 tRNAs derive from the
processing of this polycistron. The L-strand gives rise to a single
polycistron starting at the 5′-end of the RNA 18 (position 407),
154 bp away from the H1 initiation point, from which the eight
tRNAs and the ND6mRNA are derived. Moreover, the H-strand
replication requires short RNA primers originated by the
processing of the L-strand promoter transcripts. Consequently,
replication of mammalian mtDNA is linked and dependent on
mitochondrial transcription, although a new mechanism of
replication has recently been described [12,13]. The precise
location and mechanism for H2 and L-strand transcriptionFig. 1. Genetic and transcription map of human mtDNA. The two internal circles rep
(tRNAs) and blue (protein coding genes). External circles represent the RNAs transcri
or H2 transcription units) and light strand (in pink). ND1 to ND6 are subunits 1–6 of
CO I, CO II and CO III, are subunits of cytochrome c oxidase (complex IV) and ATP6
the one letter code of the corresponding amino acid. OH and OL represent replication
replication. H1, H2 and L indicate initiation points for the three transcription units of th
of the figure, indicate the direction of replication and transcription of both strands.termination is unknown [14], although the finding of H-strand
ESTs with polyadenylation sites located immediately upstream
of the H1 site suggests that this point might be the termination
site for the second transcription unit of the H strand [15], as
previously suggested [16].
The polycistronic primary transcripts synthesized from the
three initiation sites are processed, according to the “tRNA
punctuation” model, to give rise to the mature rRNAs, mRNAs
and tRNAs after the precise endonucleolytic cleavage on both
sides of the tRNA molecules [8,17]. According to this model,
the tRNA sequences on the nascent RNA chains would acquire
the cloverleaf structure and act as the signals for the processing
enzymes. The processing of the polycistronic molecules re-
quires precise endonucleolytic cleavages at the 5′- and 3′-end of
the tRNAs, the addition of the CCA to the 3′-end of the tRNAs,
a polyadenylation activity for mRNAs and rRNAs, and, finally,
the post-transcriptional modification of a subset of tRNA and
rRNA nucleotides.
The 5′-endonucleolytic cleavage occurs first [18] and is
performed by a mitochondrial RNase P [19,20]. The enzyme
responsible for the 3′-end cleavage activity is a tRNAase Z [21].
The addition of the CCA to the 3′-end of the tRNAs is
performed by an ATP(CTP):tRNA nucleotidyltransferase. Thisresent both mtDNA strands with the encoded genes in yellow (rRNAs), red dots
bed from the heavy strand (in orange or in blue for the RNAs derived from the H1
NADH dehydrogenase (complex I); cyt b, cytochrome b subunit of complex III;
and ATP8, subunits of ATP synthase (complex V). tRNA genes are indicated by
origins for the H- and L-strand, respectively, according to the classical model of
e H- and L-strand, respectively. Arrows at the OH and OL, and in the outside part
Fig. 2. Antisense-tRNAGlu and tRNAGlu sequences before processing. The first one is transcribed from the H-strand and the tRNAGlu from the L-strand. Therefore,
both will have complementary sequences and will be able to adopt cloverleaf structures, although the antisense sequence will not be a bone fide tRNA. The 3′-end of
RNA 5 (mRNA for ND5), upstream of the antisense-tRNAGlu, is not indicated in the figure since it has not been mapped.
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avoiding its own removal from the tRNA. Additional activities
are needed for tRNA modification [23,24].
As mentioned before, the mRNAs are polyadenylated with
tails of ∼55 A [25,26]. Interestingly, rRNAs transcribed from
H1 are not adenylated [27] or contain short tails (1–10 residues)
of adenine at their 3′-end. However, the rRNAs transcribed
from H2 are polyadenylated [8] and they are considered end-
products (possibly waste products), rather than precursors for
ribosome formation [27]. Polyadenylation is performed by a
mitochondrial poly(A)-polymerase [28], and in many cases it
even produces the stop codons of some mRNAs [17]. The
function of the 3′ poly(A) tails for RNA stability is still un-
known. The addition of a 3′-end poly(A) extension in bacteria
and organelles mediates rapid RNA decay [29]. However, in
human mitochondria, a correlation between tail length and RNA
stability has been observed [30]. Surprisingly, internal poly-
adenylation seems to be responsible for rapid RNA degradation
in human mitochondria [15].
There are some cases in which there is not any tRNA
separating the other RNAs of the polycistronic molecule. Such
is the case of RNA 14 and 15. In this case, it is quite likely that
another secondary structure can be recognized by the processing
machinery. Mitochondrial mRNAs have considerable second-
ary structure in their 5′-terminal regions [31] and the first stem
of the COIII mRNA contains an antideterminant CCA sequence
in its 3′-region (see Fig. 9A in [31]). This fact might explain the
processing only in the 5′-side of this secondary structure and
then the production of the mature mRNA for COIII [32]. Also,
RNA 5, 9 and 11 have an “antisense-tRNA” at either 3′- or 5′-
end. Interestingly, RNAs 9 and 11 starts 9 and 4 nt away fromtheir 5′ antisense-tRNAs while the RNAs located between true
tRNAs are processed at the nucleotide closer to the tRNA
[17,27,33]. Thus, it is possible that the antisense-tRNAs and the
true tRNAs are not equally recognized by the processing
machinery (Fig. 2). It is not known whether these antisense-
tRNAs have any function or whether they are rapidly degraded.
However, it has been shown that H-strand transcripts, both
codogenic and non-codogenic, are more stable than L-tran-
scripts [34].
The mitochondrial mRNAs start directly at the initiation
codon or have an extremely short untranslated 5′-end (1–3 nt),
lacking the typical features of other mRNAs such as 5′-end
untranslated regions or the 5′-end ‘cap’ structure [33]. Mito-
chondrial mRNAs do not contain recognizable ribosome
binding sites and it seems that they are translated from the
first initiation codon at the 5′-end. In prokaryotic mRNAs the
5′-end leader sequence contains a stretch of nucleotides
complementary to a region near the 3′-end of the rRNA.
Eukaryotic mRNAs employ a 5′ terminal modification as a
primary recognition signal. A particular protein mediates the
binding of these mRNAs to the ribosome. Therefore, mamma-
lian mitochondrial ribosomes must utilize different mechanisms
to initiate protein synthesis. In this sense, mitochondrial
mRNAs contain considerably secondary structure near their 5′
ends and initiation factors seem to be required for the proper
recognition of these mRNAs as a prerequisite for initiation of
protein synthesis [31].
Most mature poly(A)-RNAs correspond to a single gene but
two of them, the mRNA for ND4 and ND4L subunits (RNA 7)
and the mRNA for ATP6 and ATP8 subunits (RNA 14) contain
two overlapping reading frames. The way by which the two
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translated is still not completely understood. Two alternative
mechanisms were proposed [35]. The first one involves
translating each reading frame pair as a single polypeptide.
This can happen if the ribosome slipped back one base during
the translation of ATP8, which would result in premature
termination at out-of-phase codons, followed by reinitiation at
the ATP6 initiation codon. In the second one, the translation
may require ribosome binding and initiation from a site in the
first reading frame. The lack of a ribosome attachment site in the
RNA 14, upstream of the ATP6 reading frame discard an
independent entry site for ribosomes destined to translate the
downstream reading frame [36]. However, other evidences
support the ATP6 translation by initiation within the ATP8 gene
[37].
3. Basic transcription machinery
MtDNA transcription requires an organelle-specific RNA
polymerase (mtRPOL or POLRMT) [38] and at least three
transcription factors: TFAM (or mtTFA) [39,40] and either
TFB1M or TFB2M for initiation [41,42] and mTERF for
termination of the transcription unit starting at H1 [11,43,44]
(Fig. 3).
The mtRPOL, encoded in the nuclear DNA (nDNA)
(chromosome 19p13.3), is homologous to phage polymerases
[38,45]. The cDNA for the human mtRPOL contains 3831 bp
and codes for a protein of 1230 amino acids that, once it is
internalized into mitochondria, eliminates 41 residues of the N-
terminus giving rise to a mature protein of 1,189 amino acids.
The amino-terminal region of the human mtRPOL contains two
pentatricopeptide repeat motifs (PPR) that seem to be im-
plicated in RNA processing in organelles [46]. In the absence of
transcription factors, the h-mtRPOL is unable to recognize the
mitochondrial promoters and shows little and only non-specific
activity [39,47].
TFAM was the first mitochondrial transcription factor iden-
tified. The 246 amino acids of the human pre-protein are en-
coded on chromosome 10q21 of the nDNA, that results in a
mature factor of 202 residues after import and elimination of the
42 N-terminus amino acids. TFAM contains two HMG-boxesFig. 3. Schematic representation of the human mitochondrial control and transcrip
transcription. The non-coding regulatory region, rRNA, ND1 and tRNA sequences ar
the rDNA region ending at the 3′-end of the 16 S rRNA gene. This termination require
the tRNALeu gene located just downstream of the rDNA area. Initiation at H2 transcrib
a polycistronic RNA from which derives the RNA primer for initiation of H-stran
upstream of the transcription initiation points H1 and L, and to other sequences such a
TFB2M would deliver the enzyme to the promoter region occupied by TFAM.separated by a linker region and a basic C-terminal tail, each
HMG-box has DNA-binding activity [40,48]. The C-terminal
tail is required for promoter-specific transcription. Binding sites
for TFAM are found upstream of the two more active
transcription initiation points in the control region of the
mtDNA (H1 and L), but both the binding and transcription
stimulation activities are higher for the L promoter (LSP) than
for the H1 promoter (HSP1) [40,49,50]. TFAM is able to wrap,
bend and unwind DNA in vitro with a low degree of sequence
specificity [48,51]. Since this protein has also non-specific
DNA-binding activity, it was suggested that the main function
of this factor is maintenance of mtDNA. This is underscored by
the role it plays in transcription synthesizing RNA primers from
the L-promotor in order to initiate replication [52,53]. However,
according to the new model of mtDNA replication [12,13], this
role would be less important, since replication would not need
initiation of transcription from the L-promotor. On the other
hand, TFAM knockout mice produced by Larsson and co-
workers did not allowed discrimination between transcription
regulation and mtDNA maintenance [54], however, increasing
the intramitochondrial TFAM levels, either in organello or in
vivo, is sufficient to stimulate mtDNA transcription and pro-
bably to initiate the synthesis of replication intermediates, but
not sufficient for successful replication of full-length mtDNA
copies [55,56].
There are two additional mitochondrial transcription factors:
TFB1M and TFB2M [41,42]. The human TFB1M (h-mtTFB1)
and TFB2M (h-mtTFB2) are encoded in seven and eight exons
located on chromosomes 6q25.1–q25.3 and 1q44 of the nDNA,
respectively. TFB2M shows at least two orders of magnitude
more activity in stimulating specific transcription than TFB1M.
Both factors seem to directly interact with the RNA polymerase
forming a heterodimer, and, one or the other, in addition to
TFAM, are required for the accurate initiation in vitro on both
H1 and L promoters, although they seem not to be required for
transcription elongation [41]. Thus, the minimal machinery
required for in vitro transcription initiation would include
mtRPOL, TFAM, and either TFB1M or TFB2M. It has also
been shown that TFB1M has an rRNA dimethylase activity
[57]. Both, methylation and transcription activation activities
may be independent [58].tion termination regions, showing the main elements and factors involved in
e shown in grey, green, blue and pink, respectively. Initiation at H1 site transcribe
s the presence of the transcription factor, mTERF, that binds to a sequence inside
es the whole H-strand. Transcription starting at L-strand promoter (L) originates
d replication. Transcription factor TFAM binds to enhancer elements located
s the conserved sequence blocks (CSB). A heterodimer formed by mtRPOL and
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transcription initiation requires, first, the bending and wrapping
properties of TFAMand, then, the binding of TFB1Mor TFB2M
to RNA polymerase that would deliver the enzyme to the
promoter region occupied by TFAM [59].
Transcription termination at the end of the transcription unit
starting at H1 and finishing at the 3′-end of 16S rRNA gene
requires a protein, termed mTERF [11]. The human gene for
this factor contains two exons and is located on chromosome
7q21–q22. The mature protein, produced once the pre-protein
has been imported into mitochondria, has a molecular weight of
approximately 39 kDa. This factor contains three potential
leucine zippers and two separated basic binding domains in its
sequence, binds DNA as a monomer and is able to bend DNA
[44,60]. mTERF exists in mitochondria in two forms, an active
monomer and an inactive homotrimer. A rearrangement in the
interaction between leucine zippers would be responsible for the
control of the activity of mTERF. Intramolecular interactions
would maintain the tertiary structure of the active monomer,
whereas the inactive form would depend on intermolecular
interactions [61]. Recent work with rat mTERF has shown that
this factor needs to be phosphorylated in order to be functional
[62], although this fact is controversial, since the human factor
seems to function independently of this modification [63].
4. Regulation of mitochondrial transcription
Variations in physiological situations and cell types require
different energetic demands. Even more, inside the same cell,
the energy requirements may be different depending on the
existence of particular cell domains, and diverse biogenetic
programs can be observed according to the specific situations
[64]. Thus, during situations of active cell growth and division,
mitochondrial proliferation is needed, while mitochondrial
maturation or differentiation would take place during cell
differentiation. In addition, it has been described that there is a
rapid mechanism for the adjustment of mitochondrial functionFig. 4. Schematic representation of a proposed model for a double mitochondrial l
regulated in parallel by allowing a recycling of the mtRPOL between the promotersin response to local changes of ATP demands and other
extramitochondrial signals [65]. The mechanisms that regulate
mitochondrial activity during various situations may be
different and very complex since they can also overlap [66].
Changes in transcription activity and in the steady-state level
of the different mitochondrial RNA types have been reported in
diverse series of situations in mammals, for example in different
stages of development [67,68], ageing [69–71], change in cellular
energy demands [72–75] or hormonal status [65,76–81]. The
molecular mechanisms involved in the regulation of mitochon-
drial transcription, responsible for these changes, are still poorly
understood.
Transcription regulation can be operated either at the level of
initiation, termination or both. In particular, the transcription
initiation rate at the two alternative H-strand promoters would
determine the synthesis ratio of rRNAs versus H-strand
mRNAs, which is supposed to be important for protein syn-
thesis capacity [8,82]. The differential transcription of the H-
strand is regulated not only through initiation at different sites,
but also at the level of 3′-end termination of the rRNA trans-
cription unit. The transcription termination factor mTERF plays
a fundamental role in attenuation of this process [11]. As
mentioned before the activity of this factor appears to be
regulated by phosphorylation. While the DNA-binding activity
of mTERF is unaffected by the phosphorylation state, only the
phosphorylated form of the protein would be involved in ter-
mination [62]. The two alternative sites at which H-strand
transcription can be initiated are physically related. While the
activity of mTERF promotes the termination of transcripts
synthesized from the first transcription unit, initiated at H1, the
second initiation site is refractive to the activity of mTERF. It is
therefore likely that some communication exists between the
sites of transcription initiation and termination. Accordingly, a
new DNA target sequence for mTERF binding has been iden-
tified in the promoter region, albeit with a slightly lower affinity
than that for the termination mTERF recognition site [62,83].
The fact that binding sites for mTERF are present both upstreamoop. According to this model, the rDNA and L-strand transcription would be
.
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proposal that transcriptional termination and initiation are
functional linked [84] (Fig. 4). In this model the mt-rRNA
transcription unit would form a loop that facilitate the direct
transfer of the mitochondrial RNA polymerase molecules that
have terminated the transcription of nascent pre-rRNA chains to
the transcription initiation site H1. In this way, the transition to
the pool of free mtRPOL is bypassed and the efficient recycling
of this enzyme is ensued. Strong evidence for this model has
recently been obtained indicating that the mechanism underly-
ing this regulation of human mitochondrial rDNA transcription
by mTERF, involving the simultaneous interaction of this factor
with the initiation and termination sites and the resulting
looping-out of the rDNA [10].
The binding of mTERF to these two mtDNA sequences will
create two different loops, one for the rDNA transcription unit
and another one for the L-strand transcription unit (Fig. 4). The
mTERF binding site to the promoter region is located between
nucleotides 367 and 523, close to the initiation site for the L-
strand [83]. Moreover, the termination-promoting activity of
mTERF is bidirectional and, since no additional genes are en-
coded in this strand downstream of the mTERF binding site, this
factor could also act on the L-strand transcription termination
[60]. Interestingly, the rate of synthesis of rRNA is more than 15-
fold higher relative to mRNA [7,8] and the L-strand is trans-
cribed three times more frequently than the H-strand [85,86].
Thus, this difference of 5 times between the rRNA and the L-
strand transcripts synthesis might be due to the fact that the L-
strand transcription unit is 5 times larger. Moreover, there is a
parallel regulation for the expression of both transcription units
(H1 and L) and different from the whole mtDNA transcription
starting at H2 [87]. Therefore, this mitochondrial loop could
accelerate the transcription of both transcription units in a regu-
lated way via repositioning the transcription machinery without
diffusion from template DNA (Fig. 4).
Thus, a fairly complete picture is now available of mtDNA
transcription in human cells. By contrast, very little is known
about the regulation of these processes. For example, as we
have seen, the H-strand expression responds to different stimuli
than the rRNA and L-strand [87]. The mtDNA is a very com-
pact and economic genome but this does not seem to be true for
the transcription mechanisms since the L-strand is mostly non-
codogenic. Which is the evolutionary reason to maintain
transcription from both strands? ND6 is the only mitochondrial
polypeptide encoded by the L-strand and seems to be necessary
for complex I assembly [88]. Thus, a differential regulation of
ND6 expression may be a mechanism to control complex I
assembly and the entry of electrons to the respiratory chain.
Alternatively, the polyadenylated RNA 1 transcript encom-
passes most of the L-strand and therefore it could act as an
interfering RNA for H-strand transcripts. Then, a differential
regulation of both H- and L-transcription units could avoid an
interaction between them.
Screening the mitochondrial genome for binding sites for
known nuclear transcription factors revealed the presence of some
sequences with similarity to consensus sequences for twenty-one
transcription factors, known to modulate nuclear genes [89].Interestingly, the analysis of more than 2864 mitochondrial
sequences and the information collected frommitomap.org shows
a high conservation in 14 of them, thus supporting a potential role
as regulatory elements. For example, similar sequences have been
found for steroid and thyroid hormone binding nuclear receptors,
which could act as hormone response elements (HREs). These
hormones are major regulators of metabolic processes and their
receptors have been detected inmitochondria [89–95].Moreover,
gel-retardation experiments showed that they were able to bind
these HREs and that they can confer hormone-dependent ac-
tivation of reporter genes in transfection experiments [94]. All
these evidences suggest these hormone binding transcription
factors could play a regulatory role in mitochondrial functions.
Surprisingly, one of the potential HREs for glucocorticoids is
located between mitochondrial DNA positions 3228–3242 [94],
overlapping with the sequence (3229–3256) protected by the
mTERF factor [11]. Therefore, it is possible that glucocorticoids
can regulate the rDNA loop formation [94].
Thyroid hormones are key players in energy metabolism.
Hypothyroidism induces a decrease in the steady-state concen-
tration of all mtRNAs, which is most pronounced for mRNAs,
thus also changing the mRNA/rRNA ratio [76–78,80]. By using
the in organello approach, a direct effect of thyroids hormones on
the mRNA/rRNA ratio and on the protein–mtDNA interactions,
probably through changes in H-strand promoter selection, was
found. This effect was achieved with a low concentration of
hormones and was saturable [80].
The processing of the polycistrons to yield the mature RNAs
is another potential regulatory point, although available data
suggest that this process is very rapid and not limiting. More
important, it appears that changes in RNA stability determine,
along with the transcriptional rate, the final steady-state level for
each RNA species [96]. Because the mechanism of transcription
for the mtDNA H-strand ensures the same rate of synthesis of
each mRNA transcript, the differentiated steady-state levels of
the individual transcripts must be achieved by the efficiency of
their excision from the long precursor together with degradation
rate [97].
5. Mitochondrial RNA metabolism and disease
Theoretically, mutations in mtDNA sequences or in nuclear
genes involved in regulation of mitochondrial RNA metabolism
might have phenotypic consequences. In this context, a high
proportion of the somatic T414G transversion was found in the
fibroblast mtDNA molecules of aged but was absent in younger
individuals [98–100]. This transversion was also present in a
high proportion of brains, but only in a small percentage of
molecules in patients with Alzheimer disease (AD), whereas it
was completely absent in all controls [101]. This mutation is
located in the middle of the promoter core region for L-strand
transcription, at a position adjacent to a segment with high
affinity for TFAM.
Mutations in mtDNA elements related to the initiation of
transcription are not the only ones possibly associated with
particular phenotypes. The tRNALeu(UUR) is a mutational hot
spot. Eight pathological mutations have been described in the
1185J. Montoya et al. / Biochimica et Biophysica Acta 1757 (2006) 1179–1189tRNALeu(UUR) gene region that is probably protected by
mTERF binding [11], suggesting that other functions besides
those related to the normal tRNA functions may be affected by
these mutations. Thus, the A3243G transition located in the
termination site of the H1 transcription unit, substantially
decreases mTERF binding [102,103] and results in severe im-
pairment of transcription termination at the end of the 16 S
rRNA gene [104].
As previously mentioned, tRNAs are considered processing
signals and many tRNA mutations have been shown to affect
RNA metabolism. For example, the MELAS A3243G mutation
provokes a small but consistent increase in the steady-state levels
of a new RNA (RNA 19), corresponding to 16S rRNA
+tRNALeu(UUR) +ND1. This result suggests a defect on the
tRNALeu(UUR) processing [105]. Other pathologic tRNALeu(UUR)
mutations, such as 3256T, 3271C and 3302G, also increase the
levels of RNA 19 [106–108]. Mutations in other mitochondrial
tRNA genes also affect quantitatively the RNA processing
efficiency. Thus, mutations at positions 7510G, 7511G and
7512G in the tRNASer(UCN) decrease this efficiency [109], and
indeed it was shown that the 7512G mutations leads to the
accumulation of a precursor transcript [110]. In addition,
mutations at positions 7442Ci, 7443C, 7444T and 7445C and
7445G, adjacent to the 3′-end of the tRNASer(UCN) gene, have
not only quantitative but also qualitative effects on the pro-
cessing of this tRNA. The processing is produced by an aberrant
cleavage one nucleotide in the 3′-direction from the normal
processing site [109,111], however, this qualitative effect was
not found in another study for 7445C [112].
Other mtDNA mutations affect RNA stability. A two residues
microdeletion (μΔ9205) removing the ATP6 termination codon
was found in a patient with mitochondrial disease. The poly-
adenylation profile of the RNA 14 revealed substantial ab-
normalities.Most of thismutated RNA terminatedwith short poly
(A) extensions and the steady-state levels of the RNA 14 was
markedly decreased. The enhanced turnover of RNA 14 was due
to a translation-dependent deadenylation decaymechanism [113].
Besides mitochondrial mutations, trans-acting elements can
also be related to mitochondrial diseases. The TFB1M and
TFB2M initiation factors are closely related to rRNA methyl-
transferases [42]. Thus, these transcription factors can have other
roles in mitochondrial gene expression. In fact, TFB1M
expression in E. coli lacking the KsgA rRNA methyltransferase
restores dimethylation of two adjacent residues in an stem–loop in
the bacterial 16 S rRNA.Moreover, the resistance to the antibiotic
kasugamycin is reversed by expression of TFB1M. The target
adenine residues of this stem–loop are evolutionary conserved in
the mitochondrial 12 S rRNA [57]. This mitochondrial stem–loop
is close to the 3′-end of the 12 S rRNA and 28 nucleotides
downstream of a pathogenic mtDNA mutation (A1555G) that
predisposes individuals to deafness. Interestingly, there is evidence
that the nuclear genetic background influences the phenotypic
expression of this mutation. A polymorphism on chromosome 6
near the TFB1M gene, but located out of the coding region, was
implicated as a nuclear modifying locus of the 1555G mutation in
several pedigrees of mitochondrial deafness [114]. Several clues
imply that the altered TFB1M expression affects the penetrance ofthe 1555G mutation by modifying the rRNA methylation. Thus,
the methylation status of the analogous bacterial 16 S stem–loop
determines sensitivity to aminoglycosides, the same antibiotics
inducing deafness in patientswith themitochondrialmutation. The
bacterial stem–loop structure is altered by the dimethylation of the
conserved adenines what may suggests that the mitochondrial
homologue structure could be also affected [115].
We have already seen how mitochondrial mutations in tRNA
genes have been associated to different pathologic phenotypes.
Recently, a candidate gene for prostate cancer susceptibility,
ELAC2, has been identified. Several variants in this gene are
significantly associated with the occurrence of this disease.
Surprisingly, the prostate cancer susceptibility gene encodes the
tRNase Z, the enzyme required for the 3′-end processing of the
mitochondrial tRNAs [116].
The h-mtRPOL has an amino terminal extension with two
pentatricopeptide (PPR) domains, a motif found in a family of
proteins involved inRNA trafficking andmetabolism. The leucine-
rich PPR-motif containing (LRPPRC) protein, another member of
this PPR family, has recently been associated with the French-
Canadian type of themitochondrial Leigh syndrome (LSFC) [117].
This protein is located in the mitochondria and appears to bind mt-
mRNAs. It has been postulated that LRPPRC could function to
facilitate the processing, trafficking and/or translation of human
mtRNAs. The h-mtRPOL and LRPPRC may work together
coupling post-transcriptional events directly to the transcription
machinery, through the amino terminal domain of the mtRPOL.
As we have previously seen, the processing of nascent
mitochondrial RNA chains seems to proceed concomitantly
with the transcription process and polyadenylation would occur
during or immediately after this cleavage [118]. Therefore,
transcription, processing and maturation activities may form a
ribonucleo-protein complex acting together. Then, the associ-
ation between the LSFC disease and mutations in LRPPRC
probably defines a novel pathogenic mechanism in humans
involving defects in coupling during the mitochondrial gene
expression pathway [119].
6. Future prospects
An enormous effort done in Attardi's and others laboratories
unraveled the basis of mitochondrial transcription. However,
some of the earlier findings remain still unexplained and many
of them may be important in mitochondrial pathology. It is not
rare to find patients with many evidences pointing to mtDNA
disease without mtDNA “pathologic” mutations. As we have
seen, tRNA [111] or non-coding mutations [112] can affect the
RNA processing. For example, if the proposed secondary
structure for RNA 15 is true, it would be possible that mutations
in the first stem of this RNA could affect its processing. Inter-
estingly, only two polymorphisms have been described in this
stem in 2864 mitochondrial sequences and the mitomap data-
base, one of them rebuilding a Watson–Crick base pair and the
other one (nt 9212, a synonymous mutation) in a patient with
Alzheimer disease. Moreover, synonymous changes affecting
the stability of the mRNAs [120] or mitochondrial HREs could
also have phenotypic effects by altering the transcription factor
1186 J. Montoya et al. / Biochimica et Biophysica Acta 1757 (2006) 1179–1189binding, as already shown for nuclear HREs [121]. Therefore,
we need to be more cautious when ruling out these changes as
possible pathologic mutations [122].
Future work in order to know the finest details of the
mitochondrial transcription process and machinery is necessary
for studying other possible implications of RNA synthesis and
processing with mitochondrial diseases and may allow to define
therapeutic targets for their treatment.
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